Granzyme H of Cytotoxic Lymphocytes Is Required for Clearance of the Hepatitis B Virus through Cleavage of the Hepatitis B Virus X Protein

Haidong Tang, Chong Li, Li Wang, Honglian Zhang and Zusen Fan

_J Immunol_ published online 7 December 2011
http://www.jimmunol.org/content/early/2011/12/07/jimmunol.1102205
Granzyme H of Cytotoxic Lymphocytes Is Required for Clearance of the Hepatitis B Virus through Cleavage of the Hepatitis B Virus X Protein

Haidong Tang, Chong Li, Li Wang, Honglian Zhang, and Zusen Fan

The granule exocytosis pathway of cytotoxic lymphocytes plays critical roles in eradication of intracellular viruses. However, how hepatitis B virus (HBV) is cleared has not been defined. To clarify immune mechanisms underlying inhibition of the HBV replication, the relationship between granzyme H (GzmH) and HBV clearance was investigated. In this study, we found that the granule exocytosis pathway can inhibit HBV replication without induction of cytolysis of the infected cells. GzmH is essential for HBV eradication. The HBx protein (HBx), required for the replication of HBV, is cleaved at Met79 by GzmH. GzmH inhibitor can abolish GzmH- and lymphokine-activated killer cell-mediated HBx degradation and HBV clearance. An HBx-deficient HBV is resistant to GzmH- and lymphokine-activated killer cell-mediated viral clearance. Adoptive transfer of GzmH-overexpressing NK cells into HBV carrier mice facilitates in vivo HBV eradication. Importantly, low GzmH expression in cytotoxic lymphocytes of individuals is susceptible to HBV infection and hepatocellular carcinoma. These results indicate that GzmH might be detected as a potential parameter for diagnosis of HBV infection and hepatocellular carcinoma.

Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China

Received for publication July 28, 2011. Accepted for publication November 2, 2011.

This work was supported by the National Natural Science Foundation of China (Grants 30830030, 30972676, 31128003, and 31170837), 973 Program (Grant 2010CB919102), and the Innovative Program of the Chinese Academy of Sciences (Grants XDA09010407 and KSCX1-YW-22).

Address correspondence and reprint requests to Dr. Zusen Fan, Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China. E-mail address: fanz@moon.ibp.ac.cn

The online version of this article contains supplemental material.

Abbreviations used in this article: Ad, adenovirus vector; CMA, concanamycin A; CMK, chloromethylketone; Gzm, granzyme; GzmH, granzyme H; HBsAg, hepatitis B surface Ag; HBV, hepatitis B virus; HBx, hepatitis B virus X protein; HCC, hepatocellular carcinoma; LAK, lymphokine-activated killer; m, mutant; HBsAg, recombinant hepatitis B virus X protein; RT, room temperature; SLO, streptolysin O.

Copyright © 2011 by The American Association of Immunologists, Inc. 0022-1767/11/S16.00

Materials and Methods

Cell lines, Abs, and reagents

HepG2 and HepG2.2.15 cells were cultured in DMEM medium supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin. HepG2.2.15 cells were maintained in medium containing 380 μg/ml G418. K562 cells were cultured in RPMI 1640 medium. Commercial Abs were mouse mAbs against HBx (Chemicon International), FLAG (Sigma-Aldrich), CD56-Alexa 488 (eBioscience), CD56 (Goldenbridge, Beijing, China), GzmH [a kind gift from Dr. Joseph Trapani, Peter MacCallum...
Cancer Centre, East Melbourne, VIC, Australia (15). rabbit polyclonal Ab against NM23-H1 (Santa Cruz Biotechnology), GzmH (Abcam), Alexa 488-conjugated donkey anti-mouse IgG (Molecular Probes), Alexa 594-conjugated donkey anti-rabbit IgG (Molecular Probes), PE-conjugated goat anti-mouse IgG (eBioscience), and PE-conjugated goat anti-rabbit IgG (eBioscience). Concanaamycin A (CMA), streptolysin O (SLO), and Hoechst 33342 were from Sigma-Aldrich.

Plasmid construction

Active and mutant (m) (D102N) GzmH was cloned into pET-28a with an enterokinase cleavage site before N-terminal amino acids IIGG as described (L. Wang, K. Zhang, L. Wu, S. Liu, H. Zhang, Q. Zhou, L. Tong, F. Sun, and Z. Fan, manuscript in preparation). Wild-type (WT) HBx cDNA, and its mutants were cloned into the pET-26b or pcDNA-3.1 vector. The N-terminal FLAG-tagged HBx and its mutants were cloned into pSIN-EF2-puro. The WT HBV 1.3 (HBV1.3WT) and the HBx-deficient HBV 1.3 (HBV1.3X-) sequences were amplified from HBV1.3 and HBV1.3X (provided by Dr. Weizsäcker, University of Freiburg, Freiburg, Germany) and cloned into pBabe-puro.

Retroviral infection and transfection

pSIN-2-puro constructs containing WT or mutant HBx were cotransfected into 293T cells with pPAX2 and pMD2.G. Viruses were harvested at 24, 48, and 72 h posttransfection, filtered through 0.45-μm filters, and stored at -80°C. HepG2 cells were transfected with 5 μg pFU per well. Similarly, pBabe-puro constructs containing HBV1.3WT or HBV1.3X- was cotransfected into 293T cells with pM86.0 and pCMV-VSV-G. Viruses were harvested at 24, 48, and 72 h posttransfection. Forty-eight hours post-transduction, HepG2 cells were selected in medium containing 5 μg/ml puromycin (Sigma-Aldrich). Transfection was carried out using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.

Recombinant protein expression

Recombinant HBx (rHBx), GzmB, GzmM, GzmH, and mGzmH were expressed in Escherichia coli and refolded from inclusion bodies as described previously (16). GzmA and GzmK were expressed and purified as described (17). GST and GST-tagged p53 were expressed in a Rosetta (DE3) strain and purified with glutathione Sepharose 4B beads (Amersham Pharmacia Biotech). His-tagged p53 was purified by an Ni-NTA column.

Pulldown assay

mGzmH, HBx, or GST were covalently linked to Affi-Gel 10 (Bio-Rad) according to the manufacturer’s instructions. Recombinant proteins were incubated with immobilized proteins at 4°C for 3 h. After five washes, the bound proteins were eluted in SDS-PAGE sample buffer and analyzed by immunoblotting.

Cytotoxicity assay

For each experiment, SLO was preactivated by 10 mM DTT at room temperature (RT) for 10 min, and its sublytic dose (40–100 ng/ml) was determined to load GzmH into target cells. PBMCs from healthy donors were purchased from the Beijing Blood Center and isolated by Ficoll-Hypaque gradient centrifugation. For generation of LAK cells, PBMCs were cultured with 1000 U/ml recombinant human IL-2 for 4 days. Cytolysis mediated by LAK cells was measured by a 6-h [51Cr]release assay. Target cells (1 × 10⁶) were labeled with 200 μCi [51Cr] at 37°C for 1 h. After a complete wash, target cells were plated at 1 × 10⁵ cells/well. LAK cells were treated at the indicated E:T ratios. After 6 h of incubation, the supernatants were harvested, and the radioactivity was measured as previously described (18). For inhibition assay, LAK cells were pretreated with 500 nM CMA for 2 h or with 100 μM GzmH inhibitor for 1 h before incubation with target cells.

Cleave assay

rHBx or cell lysates were incubated at 37°C for the indicated times with different concentrations of GzmH or mGzmH in 20 μl cleavage buffer (20 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1 mM MgCl₂, and 1 mM CaCl₂). The reactions were stopped by adding 5× SDS loading buffer. Samples were subjected to SDS-PAGE for immunoblotting (19).

Confocal microscopy

HepG2 cells were transfected with FLAG-HBx. Forty-eight hours post-transduction, cells were loaded with mGzmH plus SLO for 1 h, washed, and fixed with 4% paraformaldehyde for 30 min at RT. After being permeabilized with 0.1% Triton X-100 for 10 min, the cells were incubated with anti-FLAG mAb and anti-GzmH pAb overnight at 4°C. The treated cells were further stained with Alexa 488-conjugated donkey anti-mouse IgG or Alexa 594-conjugated donkey anti-rabbit IgG for 1 h at RT followed by staining with 5 μg/ml Hoechst 33342 for 10 min and observed using laser-scanning confocal microscopy (Olympus FV500 microscope; Olympus).

Real-time PCR

Genomic DNA was isolated by standard phenol-chloroform extraction procedure. Total RNA was isolated using TRIzol reagent and reversely transcribed with Superscript II (Invitrogen, Carlsbad, CA). Viral contents were measured in a Rotor-Gene 6000 analyzer (Corbett Research, Sydney, NSW, Australia). HBV DNA was quantified after normalizing to β-actin, whereas 18S rRNA was used as the internal control for RNA. The primers were as follows: HBV sense, 5'-CCCCGTGGTTCCTCTTAATTCC-3'; HBV antisense, 5'-GTCCGAAGGTTGTTGACAGC-3' (20); β-actin sense, 5'-CTAGTTGGCAGTTACACG-3'; β-actin antisense, 5'-ACCTTCACCCTGTCAGTTT-3'; rRNA sense, 5'-ACCCGACCTAGAATATTAGGA-3'; and rRNA antisense, 5'-GGTCATGTTCCAGAAACA-3'.

Southern blot

For the purification of cytoplasmic HBV DNA, cells were washed twice with ice-cold PBS and lysed in a lysis buffer (50 mM Tris-HCl [pH 7.4], 1 mM EDTA, and 1% Nonidet P-40) for 15 min at 4°C. After centrifugation for 5 min at 12,000 rpm, supernatants were added to EDTA (25 mM). Proteins were digested with 0.5 mg/ml proteinase K and 1% SDS for 2 h at 37°C. Nucleic acids were isolated by standard phenol-chloroform extraction procedure; HBV DNA was separated on a 1% agarose gel, blotted onto a nylon membrane (Hybond N+), and hybridized with a 32P-labeled full-length HBV fragment.

Adaptive transfer of NK cells to HBV carrier mice

cDNA of GzmM or mGzmH with the signal peptide and prodipeptide sequences were cloned into the pShuttle-CMV vector under the control of the CMV promoter. Recombinant adenovirus vectors (Ad-GzmH and Ad-GzmM) were produced by Transgen Bioengineering Institute (provided by Dr. Weizsa¨ cker, University of Freiburg, Freiburg, Germany). The recombinant viruses were coinjected into the liver of SLC/Hsd:ICR:9C mice (Harlan-Olac, Bicester, UK) under anesthesia. Naïve Balb/c mice were used as recipients. All animal experiments were performed in accordance with the guidelines for the care and use of laboratory animals of the National Institutes of Health.

Real-time PCR

Genomic DNA was isolated by standard phenol-chloroform extraction procedure. Total RNA was isolated using TRIzol reagent and reversely transcribed with Superscript II (Invitrogen, Carlsbad, CA). Viral contents were measured in a Rotor-Gene 6000 analyzer (Corbett Research, Sydney, NSW, Australia). HBV DNA was quantified after normalizing to β-actin, whereas 18S rRNA was used as the internal control for RNA. The primers were as follows: HBV sense, 5'-CCCCGTGGTTCCTCTTAATTCC-3'; HBV antisense, 5'-GTCCGAAGGTTGTTGACAGC-3' (20); β-actin sense, 5'-CTAGTTGGCAGTTACACG-3'; β-actin antisense, 5'-ACCTTCACCCTGTCAGTTT-3'; rRNA sense, 5'-ACCCGACCTAGAATATTAGGA-3'; and rRNA antisense, 5'-GGTCATGTTCCAGAAACA-3'.
mGzmH) were prepared as described previously (21). Mouse NK cells were isolated from splenocytes through a positive NK isolation kit (Miltenyi Biotec) and infected with Ad-GzmH or Ad-mGzmH at 300 PFU/cell for 6 h. pAA V-HBV 1.2 plasmid was a kind gift from Dr. Ding-Shinn Chen (Taipei, Taiwan). C57BL/6 mice (male, 6–8 wk old) were purchased from Vitalriver (Beijing, China). HBV carrier mice were established as described (22). GzmH- or mGzmH-overexpressed NK cells were transferred to HBV carrier mice. All animals were housed in the institute’s P2 mouse facility. This study was performed in accordance with the Guide for the Care and Use of Laboratory Animals of China. The protocol was approved by the Animal Welfare and Research Ethics Committee of the Institute of Biophysics, Chinese Academy of Sciences (permit number SYXK2009100).

**ELISA and immunohistochemistry assay**

Mouse sera were collected at the indicated time points and detected for hepatitis B surface Ag (HBsAg) by an HBsAg ELISA kit (Kehua, Shanghai, China) according to the manufacturer’s instructions. The livers were fixed with 4% paraformaldehyde, embedded, sliced, and stained with rabbit anti-HBc Ab (Maxim, Fuzhou, China) followed by hematoxylin staining. Normal and HCC human liver sections were purchased from Alenabio (Xi'an, China) and stained with anti-CD56 and anti-GzmH Abs.

**NK cell and GzmH analysis in peripheral blood samples**

PBMCs were isolated from healthy donors, chronic HBV carriers, and HCC patients. Serum HBsAg level was determined by ELISA, and alanine transaminase level was measured by using an alanine transaminase kit (Biosino, Beijing, China). PBMCs were lysed by adding 5% SDS loading buffer and analyzed for GzmH expression. PBMCs were fixed and permeabilized with a Fix & Perm kit (Sizhengbai, Beijing, China), stained for GzmH and CD56, followed by flow cytometry using an FACSCalibur (BD Biosciences). Peripheral blood samples of chronic HBV carriers and HCC patients were from the Third Hospital of Peking University (Beijing, China). All patients gave written informed consent, and the study was approved by the Ethical Review Board of the Third Hospital of Peking University.

**Results**

**HBV clearance requires cytotoxic granule-mediated pathway**

Two reports showed that GzmH eradicates intracellular viruses independently of induction of cytolysis (3, 11). We obtained a similar result as shown in the Fig. 1A. We observed that LAK cells inhibited HBV replication without apparent cytolysis of target host HepG2.2.15 cells. In contrast, LAK cells could cause cytolytic to tumor cells (Fig. 1A). To determine whether granule exocytosis is involved in the clearance of HBV, we incubated HepG2.2.15 cells with LAK cells at the E:T ratio of 30. HepG2.2.15 cell line is a human hepatoblastoma cell line that contains an integrated HBV genome and can produce infectious HBV particles (23). Total genomic DNAs were isolated, and viral titers were measured by Southern blotting and real-time PCR at 0, 3, and 6 h after incubation. We found that HBV replication was significantly inhibited by LAK cells (Fig. 1B, 1C). CMA, an inhibitor of cytotoxic exocytosis, could remarkably block the LAK cell-mediated viral clearance. These results indicate that granule pathway participates in the clearance of HBV, and intracellular HBV clearance is not due to cytolysis of the infected cells.

---

**FIGURE 2.** GzmH inhibits HBV replication. A, GzmH, not other Gzms, suppresses HBV replication. HepG2.2.15 cells (4 × 10^5) were treated with 0.25 or 0.5 μM GzmA, GzmB, GzmK, GzmM, or GzmH in the presence of SLO (80 ng/ml) at 37˚C for 6 h. Genomic DNAs were extracted, and viral titers were measured by real-time PCR. B, GzmH-mediated viral inhibition requires its enzymatic activity. HepG2.2.15 cells (4 × 10^5) were treated with 100 nM GzmH or mGzmH in the presence of SLO at 37˚C for 6 h. Genomic DNAs were measured as above. C, GzmH represses viral DNA replication, but not RNA. HepG2.2.15 cells were treated as in B. Cells were harvested, and HBV RNA levels were determined by quantitative RT-PCR. HBV RNA levels were normalized to that of 18S rRNA detected in the same sample. D, HepG2.2.15 resists cell death induced by GzmH. ^51Cr-labeled K562 or HepG2.2.15 cells were treated with 100 nM GzmH or mGzmH plus SLO at 37˚C for 6 h. Cytotoxicity was assessed by release of ^51Cr. Data are the means of six independent experiments for each cell line. E, GzmH inhibitor can abolish LAK-mediated viral replication. For inhibition of GzmH, LAK cells were pretreated with 100 μM GzmH inhibitor for 1 h before coincubation. Genomic DNAs were measured as above. **p < 0.01. HI, GzmH inhibitor.
GzmH inhibits HBV replication

To further explore which component is responsible for the viral inhibition, all five human cytotoxic Gzms (GzmA, GzmB, GzmK, GzmM, and GzmH) were loaded into HepG2.2.15 cells in the presence of a sublytic concentration of SLO (40–100 ng/ml). Our laboratory compared several delivery agents to load granzymes (Gzms) into target cells, including perforin, SLO, and a cationic lipid protein transfection agent, Pro-ject (7, 21). We found SLO was efficiently delivered Gzms into target cells to induce cytolysis with similar kinetics of perforin delivery, which is in agreement with a previous report (6). Among all five Gzms examined, GzmH inhibited HBV replication in the most efficient way (Fig. 2A). All of the Gzms were used in the concentrations of 0.25 and 0.5 μM, and they were all enzymatic active, as detected by their synthetic substrates (Supplemental Fig. 1). We further found that GzmH disrupted replication of HBV DNA, but not RNA (Fig. 2B, 2C). The enzymatically inactive mGzmH (D102NGzmH) plus SLO did not repress viral replication (Fig. 2B). Thus, the viral clearance needs its enzymatic activity. GzmH loading into HepG2.2.15 cells did not cause apparent cytolysis (Fig. 2D), which is reminiscent of attack by LAK cells. By contrast, GzmH induced ∼50% death in K562 cells. GzmH and SLO alone or mGzmH plus SLO caused comparable death. Based on our structural analysis and peptide screening, we designed a specific inhibitor, Ac-PTSY-CMK, that only efficiently blocks the enzymatic activity of GzmH, not other Gzms or relevant enzymes (L. Wang et al., manuscript in preparation). This Ac-PTSY-CMK inhibitor was synthesized with acetylated-Pro at the P4 position and chloromethylketone (CMK)-linked Tyr at the P1 site, an irreversible inhibitor that blocks GzmH through snugly docking into the pocket of the GzmH. LAK cells were pretreated with the GzmH inhibitor before coincubation with HepG2.2.15 cells. The GzmH inhibitor was able to block LAK cell-mediated viral clearance (Fig. 2E). These results indicate that GzmH participates in HBV clearance.

GzmH associates with the HBx protein

The HBx protein is a multifunctional regulator that is essential for HBV replication both in vitro and in vivo (13, 14). Because HBx is essential for HBV replication, we wanted to detect whether GzmH suppresses viral replication through association with the HBx protein. rHBx was expressed in E. coli and refolded from inclusion bodies as described previously (16). The activity of refolded HBx was confirmed by a GST-pulldown assay with recombinant p53, a known HBx-interacting protein (24). Enzymatically inactive mGzmH (D102NGzmH) plus SLO did not repress viral replication (Fig. 2B). To test whether HBx is a direct substrate of GzmH, rHBx was incubated with different doses of GzmH for 2 h or with 0.1 μM GzmH for different time points. Native HBx was degraded in a dose- and time-dependent manner (Fig. 4B), whereas the mutant GzmH had no activity. NM23H1 was unchanged as a loading control. However, we were unable to observe any processed products of HBx, which may be degraded by other enzymes activated by GzmH. To further verify that HBx degradation by GzmH is physiologically relevant, HBx-transduced HepG2 cells were loaded with GzmH plus SLO. GzmH was able to degrade native HBx of intact cells (Fig. 4C). GzmH and SLO alone or mGzmH plus SLO did not cause HBx degradation. NM23H1 was unchanged as a good loading control.

GzmH cleaves HBx at Met79

GzmH has a preference for Phe, Tyr, and Met at the P1 site (10). To test whether HBx is a direct substrate of GzmH, rHBx was incubated with active GzmH or mGzmH. GzmH began to cleave HBx at 20 nM, and HBx was completely degraded at 100 nM (Fig. 4A, upper panel). GzmH started to cleave HBx by 10 min, and HBx was almost processed by 30 min (Fig. 4A, lower panel). By contrast, mGzmH had no cleavage activity. Thus, degradation of HBx requires enzymatic activity of GzmH. To further detect whether GzmH can proteolyze native HBx, we transduced HBx in HepG2 cells and lysed cells 48 h posttransduction. Cell lysates were incubated with different doses of GzmH for 2 h or with 0.1 μM GzmH for different time points. Native HBx was degraded in a dose- and time-dependent manner (Fig. 4B), whereas the mutant GzmH had no activity. NM23H1 was unchanged as a loading control. However, we were unable to observe any processed products of HBx, which may be degraded by other enzymes activated by GzmH. To further verify that HBx degradation by GzmH is physiologically relevant, HBx-transduced HepG2 cells were loaded with GzmH plus SLO. GzmH was able to degrade native HBx of intact cells (Fig. 4C). GzmH and SLO alone or mGzmH plus SLO did not cause HBx degradation. NM23H1 was unchanged as a good loading control. HBx degradation was completely blocked by the GzmH
inhibitor at an inhibitor/effector ratio of 4:1 (Fig. 4F). Moreover, the GzmH inhibitor could significantly inhibit native HBx proteolysis mediated by LAK cells at the E:T ratio of 5 (Fig. 4G). The partial inhibition of HBx cleavage by the GzmH inhibitor may be caused by its inefficient entry or degraded by other enzymes activated by LAK cells.

**HBx-deficient HBV is resistant to clearance by GzmH or LAK cells**

We established a stable HepG2 cell line transduced with the WT HBV 1.3 (HBV1.3WT) or the HBx-deficient HBV 1.3 (HBV1.3X-). The sequence of HBx-deficient HBV 1.3 was identical to WT HBV 1.3, except for one point mutation introduced within the HBx coding region, which prevents the synthesis of HBx protein (27). The replication rate of the HBV1.3WT was 7-fold higher than that of the HBx-deficient HBV1.3X- (Fig. 5A), which is consistent with a previous report (28). HepG2-HBV1.3WT or HepG2-HBV1.3X- cells were treated with GzmH plus SLO, and the viral titers were measured. Fold decrease was calculated as the titer before GzmH loading divided by that after GzmH loading. As expected, GzmH dramatically inhibited viral replication in HBV1.3WT cells (the inhibitory rate was ~33-fold) (Fig. 5B), whereas GzmH showed much less inhibitory role in HBV1.3X- cells (the inhibitory rate was ~6-fold). Similarly, HBV1.3X- cells appeared to be resistant to LAK cell-mediated clearance (Fig. 5C). These results suggest that GzmH can repress HBV replication by degradation of HBx protein.

**Adoptive transfer of GzmH-overexpressed NK cells facilitates HBV clearance in mice**

We established an HBV-infected mouse model by hydrodynamic injection of pAAV-HBV 1.2 plasmids as described (22). The serum HBsAg levels became steady 2 to 3 wk after injection and lasted for >2 mo. To verify whether GzmH is able to facilitate HBV clearance in vivo, we isolated NK cells from the spleen of a healthy C57BL/6 mouse and transduced with Ad-GzmH or Ad-mGzmH. GzmH was expressed and its active form was processed in mouse NK cells (Fig. 6B). GzmH- or mGzmH-overexpressed...
NK cells were transferred to HBV carrier mice, as shown in Fig. 6A. GzmH-overexpressed NK cells facilitated clearance of HBV more effectively than that of mGzmH-overexpressed NK cells (Fig. 6C). Serum HBsAg levels were undetectable in some GzmH-overexpressed mice after 8 d transfer. HBcAg<sup>+</sup> hepatocytes were very rare in livers of GzmH-overexpressed mice (Fig. 6D, left panel). However, more HBcAg<sup>+</sup> hepatocytes appeared in livers of mGzmH-overexpressed mice. The average percentages of HBcAg<sup>+</sup> hepatocytes were quantified (Fig. 6D, right panel).

**Low expression of GzmH is susceptible to HBV infection**

To further determine the relationship of GzmH expression and HBV infection, we isolated human PBMCs from healthy donors and chronic HBV carriers. GzmH expression was extremely low or undetectable in chronic HBV carriers (Fig. 7A). By contrast, GzmH was expressed in healthy donors. These data are representative of all the detected healthy donors (<i>n</i> = 22) and chronic HBV carriers (<i>n</i> = 17). Similar results were obtained by flow cytometry analysis (Fig. 7B). Percentages of GzmH<sup>+</sup>NK cells in chronic HBV carriers were much less than those of healthy donors (<i>p</i> < 0.05, **<i>p</i> < 0.0001).

**Discussion**

Cytotoxic lymphocytes, including NK cells and CTLs, play important roles in viral clearance through the granule exocytosis pathway (29). GzmH is mainly expressed at a high level in NK cells (15), which suggests that GzmH may play an important role in innate immunity against pathogens or transformed tumors. We and Fellows et al. previously demonstrated that GzmH can induce apoptosis of target tumor cells using different death pathways (5, 6). Andrade et al. (3) found direct cleavage of adeno viral components (DNA-binding protein and 100K) by GzmH blocked virus replication. In this study, we found that GzmH directly cleaves the viral HBx protein of HBV, leading to disruption of virus replication without cell death. Low expression of GzmH in NK cells is susceptible to HBV infection and HCC.

Because viruses are intracellular pathogens, killing the infected host cell has been considered an ultimate pathway to eradication of the infection. The accepted dogma is that complete clearance of intracellular viruses depends on the destruction of infected cells by NK/CTL cell-mediated cytotoxicity (30). However, two reports demonstrated that GzmH exerts antiviral activity independently of induction of cell death (3, 11). In this study, we found that eradication of HBV by LAK cells or GzmH is not dependent on induction of cytolysis either. By contrast, LAK cells or GzmH can induce cell death of target tumor cells (Figs. 1C, 2D). These suggest that eradication of different pathogens by LAK cells or GzmH might use distinct granule exocytosis pathways. Interestingly, two recent reports showed that GzmA and GzmK can induce production of proinflammatory cytokines to eliminate pathogens without induction of cytolysis (31, 32).

Chronic infection of HBV is mainly established by vertical transmission. Impaired HBV-specific immune responses cannot efficiently eliminate the infected hepatocytes (33). However, immunocompetent adults typically result in acute hepatitis, and the virus is rapidly cleared without long-term consequences (12, 34). So it is believed that both innate and adaptive immune responses are involved in the control of HBV in humans (35). In this study, we demonstrated that low expression of GzmH is susceptible to HBV infection. GzmH participates in the inhibition of viral replication. Adoptive transfer of NK cells with overexpression of human GzmH accelerates viral eradication in HBV carrier mice. Our data indicate that the granule exocytosis pathway plays a critical role in clearance of HBV. A recent clinical report showed that NK cells had faster kinetics than HBV-specific T cells in very early HBV infections (36). This observation and our data imply that innate effector NK cells play an essential role in the elimination of HBV infection. However, this notion was not achieved by NK cell- and perforin-deficient mouse strains with an HBV infection model (20). This may be because the mouse model cannot mimic real HBV infection in humans.

Because HBV cannot infect mice, no ideal mouse models have been established to mimic genuine HBV infection in humans. GzmH is predominantly expressed in human NK cells regardless of the activation status (15). It suggests that GzmH may exert critical roles in innate immunity induced by NK cells. In this study, we found that GzmH, not other Gzms, takes part in inhibition of HBV replication, which is in agreement with clinical evidence (36). Up to date, no murine homolog has been identified for human GzmH. Murine GzmC is presumed to be a counterpart of human GzmH.
FIGURE 7. Low expression of GzmH is susceptible to HBV infection. A and B, GzmH is very low or undetectable in PBMCs of chronic HBV carriers. PBMCs were isolated from healthy donors and chronic HBV carriers followed by immunoblotting. A, NM23H1 and β-actin were used as loading controls. B, Dot plots of GzmH staining for a healthy donor and a chronic HBV carrier. Data shown are representative of all the detected healthy donors and chronic HBV carriers. C, Pooled data show the percentages of peripheral GzmH+ NK cells in healthy donors (n = 22) and CHB carriers (n = 17). D and E, GzmH is much less expressed in intrahepatic NK cells of HCC patients. Normal and HCC liver sections were fixed and stained for CD56 and GzmH via immunofluorescent staining. White arrows indicate GzmH+ NK cells (D). The percentages of intrahepatic GzmH+ NK cells in normal livers (n = 2) and HCC livers (n = 10) were quantified. Original magnification ×400. **p < 0.01, ***p < 0.001.

References


Acknowledgments

We thank Dr. Gang Li for help in the analysis of HBV samples, Drs. Liang Cheng, Deqing Hu, and Lei Shi for critical discussions, Drs. Fritz von Weizsäcker, Joseph Trapani, Guangxia Gao, and Ding-Shinn Chen for reagents, and Yuanyuan Chen, Zhenwei Yang, Yan Teng, and Junfeng Hao for technical assistance.

Disclosures

The authors have no financial conflicts of interest.


